Follow
Mikkel Bo Brent
Mikkel Bo Brent
Department of Biomedicine, Aarhus University
Verified email at biomed.au.dk
Title
Cited by
Cited by
Year
PTH (1–34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats
MB Brent, A Brüel, JS Thomsen
Bone 110, 244-253, 2018
372018
Abaloparatide: a review of preclinical and clinical studies
MB Brent
European Journal of Pharmacology 909, 174409, 2021
362021
A Systematic Review of Animal Models of Disuse-Induced Bone Loss
MB Brent, A Brüel, JS Thomsen
Calcified Tissue International, 1-15, 2020
362020
Teriparatide and abaloparatide have a similar effect on bone in mice
MB Brent, FE Stoltenborg, A Brüel, JS Thomsen
Frontiers in Endocrinology 12, 628994, 2021
192021
A review of the skeletal effects of exposure to high altitude and potential mechanisms for hypobaric hypoxia-induced bone loss
MB Brent
Bone 154, 116258, 2022
182022
Disuse osteopenia induced by botulinum toxin is similar in skeletally mature young and aged female C57BL/6J mice
JB Vegger, A Brüel, MB Brent, JS Thomsen
Journal of bone and mineral metabolism 36, 170-179, 2018
182018
Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice
MB Brent, JS Thomsen, A Brüel
Scientific Reports 11 (1), 12258, 2021
142021
Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies
MB Brent
Pharmacology & Therapeutics, 108383, 2023
122023
The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
MB Brent, JS Thomsen, A Brüel
Bone Reports 8, 9-17, 2018
122018
The efficacy of PTH and abaloparatide to counteract immobilization-induced osteopenia is in general similar
MB Brent, JS Thomsen, A Brüel
Frontiers in Endocrinology 11, 588773, 2020
112020
Rodent model of disuse-induced bone loss by hind limb injection with botulinum toxin A
MB Brent, A Lodberg, JS Thomsen, A Brüel
MethodsX 7, 101079, 2020
112020
Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats
MB Brent, A Brüel, JS Thomsen
Bone 160, 116417, 2022
102022
Hypobaric hypoxia deteriorates bone mass and strength in mice
MB Brent, T Emmanuel, U Simonsen, A Brüel, JS Thomsen
Bone 154, 116203, 2022
102022
Artificial intelligence-assisted identification and quantification of osteoclasts
T Emmanuel, A Brüel, JS Thomsen, T Steiniche, MB Brent
MethodsX 8, 101272, 2021
92021
Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice
MB Brent, A Lodberg, FD Bromer, BCJ van der Eerden, M Eijken, A Brüel, ...
Bone 142, 115692, 2021
82021
Animal models of disuse-induced bone loss: study protocol for a systematic review
MB Brent, A Brüel, JS Thomsen
Systematic Reviews 9, 1-6, 2020
72020
Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice
TG Sørensen, MB Brent, JS Thomsen, A Brüel
Bone 131, 115183, 2020
72020
The effect of normobaric intermittent hypoxia therapy on bone in normal and disuse osteopenic mice
FD Bromer, MB Brent, M Pedersen, JS Thomsen, A Brüel, CB Foldager
High Altitude Medicine & Biology 22 (2), 225-234, 2021
62021
Effect of acetazolamide and zoledronate on simulated high altitude-induced bone loss
MB Brent, U Simonsen, JS Thomsen, A Brüel
Frontiers in Endocrinology 13, 831369, 2022
52022
Sparse dose-dependent difference in skeletal effects of short-term glucocorticoid excess in outbred Swiss mice
MB Brent, A Brüel, JS Thomsen
Endocrine and Metabolic Science, 100114, 2021
32021
The system can't perform the operation now. Try again later.
Articles 1–20